The T-body approach: potential for cancer immunotherapy

@article{Eshhar2004TheTA,
  title={The T-body approach: potential for cancer immunotherapy},
  author={Z. Eshhar and N. Bach and C. Fitzer-Attas and Gidi Grosse and J. Lustgarten and T. Waks and D. Schindler},
  journal={Springer Seminars in Immunopathology},
  year={2004},
  volume={18},
  pages={199-209}
}
ConclusionsChimeric receptors containing antibody-derived Fv or scFv as their extracellular recognition elements can redirect the specificity of T cells in an MHC-independent manner.Upon encountering their target cells, such T-bodies are able to undergo specific stimulation for interleukin/cytokine production, and kill hapten-modified or tumor cells in both in vitro and in vivo model systems. T cells expressing chimeric receptors are able to discriminate between antigen-expressing and normal… Expand
T-cell engineering for cancer immunotherapy.
TLDR
Based on the effective T-cell transduction and expansion procedures now available to support clinical investigation, improved designer TCRs and second generation CARs targeting an array of antigens are being evaluated in a range of hematological malignancies and solid tumors. Expand
T Cell Engineering.
TLDR
The general design of a CAR, the function of the different domains and the different strategies to produce redirected T cells are described, indicating the tremendous potential of redirecting T cells to become a mainstay of cancer immunotherapy. Expand
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
TLDR
Clinical trials revealed that the adoptive transfer of T cells engineered with first generation CARs represents a feasible concept for the induction of clinical responses in some tumor patients, however, further improvement is required, which may be achieved by second or third generation CAR-engrafted T cells. Expand
Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
TLDR
This review discusses the latest developments in the field of adoptive immunotherapy using genetically modified immune cells that have been transduced with either TCR or scFv receptor transgenes and used in preclinical and clinical settings as anticancer agents. Expand
The T-body approach: redirecting T cells with antibody specificity.
  • Z. Eshhar
  • Biology, Medicine
  • Handbook of experimental pharmacology
  • 2008
TLDR
The T-bodies are advantageous because their tumor recognition is not HLA-specific and, therefore, the same constructs can be used for a wide spectrum of patients and cancers. Expand
CAR T cells: Building on the CD19 paradigm
TLDR
The challenges to extend the use of CAR T cells to solid tumors and other pathologies are presented, and progress in CAR design, cell manufacturing and genome editing are highlighted, which in aggregate hold the promise of generating safer and more effective genetically instructed immunity. Expand
CAR therapy : the CD 19 paradigm
Introduction The genetic engineering of T cells provides a means to rapidly generate antitumor T cells for any cancer patient. This approach is predicated on gene transfer technology that enables theExpand
Synergistic effect of chimeric antigen receptors and cytokineinduced killer cells: An innovative combination for cancer therapy
TLDR
The characteristics of CARs which make them attractive for in cancer treatment strategies are summarized and the role ofCIK cells and the advantages of combining CIK cells with CAR-based therapy will be discussed. Expand
TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations
TLDR
A brief overview of the TCR engineering-based cancer immunotherapy approach, its advantages, and the current limitations is provided. Expand
The promise and potential pitfalls of chimeric antigen receptors.
TLDR
If the immunogenicity of CARs can be averted, the versatility of their design and HLA-independent antigen recognition will make CARs tools of choice for T cell engineering for the development of targeted cancer immunotherapies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
TLDR
It is shown that T cells can be gene modified to react in vivo against tumor antigens, defined by mAbs, which is potentially applicable to a number of neoplastic and infectious diseases and may allow adoptive immunotherapy against types of cancer not previously amenable to cellular immunotherapy. Expand
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
TLDR
Surface expression of the anti-Neu/her2 chimeric genes in cytotoxic T cell hybridomas endowed them with specific Neu/HER2 recognition enabling their activation for IL-2 production and lysis of transformed cells overexpressing Neu-HER2, holding promise for the immunotherapy of cancer. Expand
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
TLDR
The results suggest that tumor cell lysis by CTLs grafted in vitro with a major histocompatibility complex-independent recognition could become a gene-therapy approach to cancer treatment. Expand
T-Bodies: Chimeric T-Cell Receptors with Antibody-Type Specificity
TLDR
To enable the generation of non-MHC-restricted T cells of predetermined specificity, the similarity between the antibody and the T-cell molecule was taken advantage and expressed in T- Cell lines chimeric T- cell receptor (cTCR) genes in which the TCR variable region is replaced by an antibody variable region of defined specificity. Expand
Endowing T cells with antibody specificity using chimeric T cell receptors
  • G. Gross, Z. Eshhar
  • Biology, Medicine
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 1992
TLDR
Chimeric TCR genes, composed of the variable domains of antibodies linked to TCR constant regions, have been used to confer antibody‐type specificity on T cells and opens new avenues to explore the role of the MHC in T cell development and maturation. Expand
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain
TLDR
To expand the spectrum of recognition of effector lymphocytes and to redirect them towards predefined targets, stable modification with chimeric receptor genes consisting of single- chain antibody variable regions linked to the gamma subunit common to the immunoglobulin (Ig)G and IgE Fc receptors is altered. Expand
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
  • G. Gross, T. Waks, Z. Eshhar
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1989
TLDR
This chimeric receptor provides the T cell with an antibody-like specificity and is able to effectively transmit the signal for T-cell activation and execution of its effector function. Expand
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
TLDR
This work designed and constructed chimeric genes composed of a single-chain Fv domain of an antibody linked with gamma or zeta chains, the common signal-transducing subunits of the immunoglobulin receptor and the TCR, which could be expressed as functional surface receptors in a cytolytic T-cell hybridoma. Expand
Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes
TLDR
It is demonstrated that the cytoplasmic portion of the TCR-zeta chain is not sufficient to activate resting T lymphocytes when cells from transgenic mice expressing a chimeric zeta receptor are used, suggesting that the triggering requirements for effector functions seem to be different in resting than in activated T cells. Expand
Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes
TLDR
T cells were endowed with anti‐IgE specificity using chimeric T cell receptors containing the variable region domain (Fv) of the 84.1c non‐anaphylactic anti‐mouse IgE monoclonal antibody (mAb) to eradicate IgE‐producing B cells in a model system. Expand
...
1
2
3
4
...